Trial Profile
Phase I-II Study of Denileukin Diftitox (ONTAK) in Patients with Advanced Refractory Breast Cancer.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Denileukin diftitox (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Adverse reactions; Therapeutic Use
- 09 Nov 2018 Status changed from active, no longer recruiting to completed.
- 09 Nov 2018 Status changed from active, no longer recruiting to completed.
- 07 Jun 2011 Planned end date changed from 1 Sep 2011 to 1 Apr 2010 as reported by ClinicalTrials.gov.